VIFOR (INTERNATIONAL) AG

Their core work

VIFOR (INTERNATIONAL) AG is the Swiss-based international arm of Vifor Pharma, a pharmaceutical company whose H2020 participation centers on cardiovascular disease and molecular drug target research. In BigData Heart, they contributed industry perspective to a large-scale clinical data platform aggregating real-world evidence on heart failure, atrial fibrillation, and acute coronary syndrome. In ReSOLUTE, they engaged with fundamental drug discovery science — specifically the identification and characterization of solute carrier membrane transporters as novel drug targets. Their role across both projects was that of an industry partner embedding pharmaceutical development interests into academic-led research consortia, rather than driving research direction themselves.

What they specialise in

How they've shifted over time

VIFOR's two H2020 projects started just one year apart, but their keyword profiles reflect two distinct scientific registers. The earlier project (BigData Heart, 2017) sits firmly in clinical epidemiology — real-world data, patient populations, cardiovascular outcomes. The later project (ReSOLUTE, 2018) shifts dramatically toward molecular biology and drug discovery infrastructure: solute carriers, deorphanisation, structural biology, proteomics, and genetic interaction networks. This trajectory suggests the company was broadening its scientific engagement beyond clinical data into the upstream stages of drug target identification, likely to feed its pipeline with mechanistically novel targets.

VIFOR was moving from clinical outcome data toward fundamental transporter biology and drug target deorphanisation, signaling interest in early-stage pipeline science rather than late-stage evidence generation.

How they like to work

VIFOR has participated exclusively as a consortium member, never as a coordinator, across both H2020 projects. Despite this passive role structure, they engaged in large collaborative networks — accumulating 32 unique partners across 11 countries from just two projects, which indicates they joined sizable, well-connected consortia rather than niche bilateral collaborations. For potential partners, this suggests VIFOR is a comfortable industry co-participant that brings pharmaceutical domain knowledge and validation capacity, but will not drive project governance or management.

VIFOR built a network of 32 unique consortium partners spanning 11 countries through only two projects, pointing to large, multi-partner European consortia rather than tightly scoped bilateral arrangements. Their geographic footprint is pan-European with a Switzerland anchor.

What sets them apart

VIFOR occupies an unusual position as a large Swiss pharmaceutical company that participates in upstream academic research — not just clinical trials or late-stage validation, but molecular target discovery (SLC transporters) and big data cardiovascular platforms. This makes them a credible industry anchor for consortia that need pharmaceutical end-user perspective, regulatory-adjacent knowledge, and eventual translation pathway without requiring a coordinator. Their non-SME status and industry classification signal the ability to absorb and act on research outputs commercially, which is often what academic consortia need to satisfy impact requirements.

Highlights from their portfolio

• ReSOLUTE
  One of the first systematic EU-funded efforts to deorphanise the entire solute carrier superfamily as drug targets, combining structural biology, proteomics, and metabolomics — a scientifically ambitious target class with significant therapeutic potential.
• BigData Heart
  A large IMI2-funded cardiovascular data initiative (Sofia ref. 116074) integrating real-world evidence across heart failure, atrial fibrillation, and acute coronary syndrome — scale and clinical breadth make it an unusually applied big-data health project.